Pentobarbital coma for management of intracranial hypertension following traumatic brain injury: Lack of early response to treatment portends poor outcomes.


Journal

American journal of surgery
ISSN: 1879-1883
Titre abrégé: Am J Surg
Pays: United States
ID NLM: 0370473

Informations de publication

Date de publication:
12 2023
Historique:
received: 14 04 2023
revised: 26 06 2023
accepted: 10 07 2023
medline: 27 11 2023
pubmed: 3 8 2023
entrez: 2 8 2023
Statut: ppublish

Résumé

Traumatic brain injury (TBI) results in the death of over 50,000 and the permanent disability of 80,000 individuals annually in the United States. Much of the permanent disability is the result of secondary brain injury from intracranial hypertension (ICH). Pentobarbital coma is often instituted following the failure of osmotic interventions and sedation to control intracranial pressure (ICP). The goal of this study was to evaluate the efficacy of pentobarbital coma with respect to ICP management and long-term functional outcome. Traumatic brain injury patients who underwent pentobarbital coma at a level 1 trauma center between 2014 and 2021 were identified. Patient demographics, injury characteristics, Glasgow Coma Scale (GCS) scores, intracranial pressures (ICPs), and outcomes were obtained from the trauma registry as well as inpatient and outpatient medical records. The proportion of ICPs below 20 for each hospitalized patient-day was calculated. The primary outcome measured was GCS score at the last follow-up visit. 25 patients were identified, and the majority were male (n ​= ​23, 92%) with an average age of 30.0 years ​± ​12.9 and median injury severity score of 30 (21.5-33.5). ICPs were monitored for all patients with a median of 464 (326-1034) measurements. The average hospital stay was 16.9 days ​± ​11.5 and intensive care stay was 16.9 ​± ​10.8 days. 9 (36.0%) patients survived to hospital discharge. Mean follow-up time in months was 36.9 ​± ​28.0 (min-max 3-80). 7 of the 9 surviving patients presented as GCS 15 on follow-up and the remaining were both GCS 9. Patients presenting at last follow-up with GCS 15 had a significantly higher proportion of controlled ICPs throughout their hospitalization compared to patients who expired or with follow-up GCS <15 (GCS 15: 88% ​± ​10% vs. GCS <15 or dead: 68% ​± ​22%, P ​= ​0.006). A comparison of the daily proportion of controlled ICPs by group revealed negligible differences prior to pentobarbital initiation. Groups diverged nearly immediately upon pentobarbital coma initiation with a higher proportion of controlled ICPs for patients with follow-up GCS of 15. Patients that do not have an immediate response to pentobarbital coma therapy for ICH universally had poor outcomes. Alternative therapy or earlier palliation should be considered for such patients. In contrast, patients whose ICPs responded quickly to pentobarbital had excellent long-term outcomes.

Identifiants

pubmed: 37532593
pii: S0002-9610(23)00327-6
doi: 10.1016/j.amjsurg.2023.07.011
pii:
doi:

Substances chimiques

Pentobarbital I4744080IR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

864-867

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Brittany M Stansbury (BM)

Creighton University School of Medicine Phoenix Regional Campus, St. Joseph's Hospital and Medical Center, 350 West Thomas Rd. Phoenix, AZ 85013, USA. Electronic address: brittanystansbury@creighton.edu.

Caitlin J Kelley (CJ)

Creighton University School of Medicine Phoenix Regional Campus, St. Joseph's Hospital and Medical Center, 350 West Thomas Rd. Phoenix, AZ 85013, USA. Electronic address: caitlinkelley@creighton.edu.

Robert F Rudy (RF)

Barrow Neurological Institute, 2910 North Third Avenue, Phoenix, AZ 85013, USA. Electronic address: robert.rudy@commonspirit.org.

Sophia S Bonnin (SS)

St. Joseph's Hospital and Medical Center Pharmacy Department, 350 West Thomas Rd. Phoenix, AZ 85013, USA. Electronic address: sophia.bonnin@commonspirit.org.

Kristina M Chapple (KM)

Creighton University School of Medicine Phoenix Regional Campus, St. Joseph's Hospital and Medical Center, 350 West Thomas Rd. Phoenix, AZ 85013, USA. Electronic address: kristina.chapple@commonspirit.org.

Laura A Snyder (LA)

Barrow Neurological Institute, 2910 North Third Avenue, Phoenix, AZ 85013, USA. Electronic address: laura.snyder@barrowbrainandspine.com.

Jordan A Weinberg (JA)

Creighton University School of Medicine Phoenix Regional Campus, St. Joseph's Hospital and Medical Center, 350 West Thomas Rd. Phoenix, AZ 85013, USA. Electronic address: jordanweinberg@creighton.edu.

Dih-Dih Huang (DD)

Creighton University School of Medicine Phoenix Regional Campus, St. Joseph's Hospital and Medical Center, 350 West Thomas Rd. Phoenix, AZ 85013, USA. Electronic address: dihdih.huang900@commonspirit.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH